دورية أكاديمية
Assessing the Relevance of Non-molecular Prognostic Systems for Myelodysplastic Syndrome in the Era of Next-Generation Sequencing.
| العنوان: | Assessing the Relevance of Non-molecular Prognostic Systems for Myelodysplastic Syndrome in the Era of Next-Generation Sequencing. |
|---|---|
| المؤلفون: | Lincango M; Laboratorio de Genética Hematológica, Instituto de Medicina Experimental (IMEX-CONICET)/Academia Nacional de Medicina, Ciudad de Buenos Aires, Argentina., Andreoli V; Hospital Universitario Privado de Córdoba, Córdoba, Argentina., Rivello HG; Hospital Italiano de Buenos Aires, Ciudad de Buenos Aires, Argentina., Bender A; Laboratorio de Especialidades Bioquímicas, Bahía Blanca, Argentina., Catalán AI; Hospital de Clínicas 'Dr. Manuel Quintela,' Facultad de Medicina, Universidad de la República, Montevideo, Uruguay., Rahhal M; Hospital de Alta Complejidad 'El Cruce Nestor Kirchner,' Florencio Varela, Argentina., Delamer R; Fundaleu, Ciudad de Buenos Aires, Argentina., Asinari M; Hospital Universitario Privado de Córdoba, Córdoba, Argentina., Orgueira AM; University Hospital of Santiago de Compostela, IDIS, Spain., Castro MB; Hospital Universitario Privado de Córdoba, Córdoba, Argentina., Osorio MJM; Fundaleu, Ciudad de Buenos Aires, Argentina., Navickas A; Hospital de Alta Complejidad 'El Cruce Nestor Kirchner,' Florencio Varela, Argentina., Grille S; Hospital de Clínicas 'Dr. Manuel Quintela,' Facultad de Medicina, Universidad de la República, Montevideo, Uruguay., Agriello E; Laboratorio de Especialidades Bioquímicas, Bahía Blanca, Argentina., Arbelbide J; Hospital Italiano de Buenos Aires, Ciudad de Buenos Aires, Argentina., Basquiera AL; Hospital Universitario Privado de Córdoba, Córdoba, Argentina., Belli CB; Laboratorio de Genética Hematológica, Instituto de Medicina Experimental (IMEX-CONICET)/Academia Nacional de Medicina, Ciudad de Buenos Aires, Argentina. |
| المصدر: | Annals of laboratory medicine [Ann Lab Med] 2024 Jul 26. Date of Electronic Publication: 2024 Jul 26. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Korean Society for Laboratory Medicine Country of Publication: Korea (South) NLM ID: 101571172 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2234-3814 (Electronic) Linking ISSN: 22343806 NLM ISO Abbreviation: Ann Lab Med Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Seoul : Korean Society for Laboratory Medicine |
| مستخلص: | Background: The Molecular International Prognostic Scoring System (IPSS-M) has improved the prediction of clinical outcomes for myelodysplastic syndromes (MDS). The Artificial Intelligence Prognostic Scoring System for MDS (AIPSS-MDS), based on classical clinical parameters, has outperformed the IPSS, revised version (IPSS-R). For the first time, we validated the IPSS-M and other molecular prognostic models and compared them with the established IPSS-R and AIPSS-MDS models using data from South American patients. Methods: Molecular and clinical data from 145 patients with MDS and 37 patients with MDS/myeloproliferative neoplasms were retrospectively analyzed. Results: Prognostic power evaluation revealed that the IPSS-M (Harrell's concordance [C]-index: 0.75, area under the receiver operating characteristic curve [AUC]: 0.68) predicted overall survival better than the European MDS (EuroMDS; C-index: 0.72, AUC: 0.68) and Munich Leukemia Laboratory (MLL) (C-index: 0.70, AUC: 0.64) models. The IPSS-M prognostic discrimination was similar to that of the AIPSS-MDS model (C-index: 0.74, AUC: 0.66) and outperformed the IPSS-R model (C-index: 0.70, AUC: 0.61). Considering simplified low- and high-risk groups for clinical management, after restratifying from IPSS-R (57% and 32%, respectively, hazard ratio [HR]: 2.8; P =0.002) to IPSS-M, 12.6% of patients were upstaged, and 5% were downstaged (HR: 2.9; P =0.001). The AIPSS-MDS recategorized 51% of the low-risk cohort as high-risk, with no patients being downstaged (HR: 5.6; P <0.001), consistent with most patients requiring disease-modifying therapy. Conclusions: The IPSS-M and AIPSS-MDS models provide more accurate survival prognoses than the IPSS-R, EuroMDS, and MLL models. The AIPSS-MDS model is a valid option for assessing risks for all patients with MDS, especially in resource-limited centers where molecular testing is not currently a standard clinical practice. |
| فهرسة مساهمة: | Keywords: Artificial Intelligence Prognostic Scoring System; Model; Molecular International Prognostic Scoring System; Myelodysplastic syndrome; Prognostic; Risk assessment; South America; Survival analysis; Therapy |
| تواريخ الأحداث: | Date Created: 20240726 Latest Revision: 20240726 |
| رمز التحديث: | 20240726 |
| DOI: | 10.3343/alm.2024.0089 |
| PMID: | 39054795 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2234-3814 |
|---|---|
| DOI: | 10.3343/alm.2024.0089 |